Our Company

1-5 of 5

Barriers and potential paths for biosimilars in the United States16 November 2018 - By Jennifer Carioto and Harsha Mirchandani - Article

Biosimilars can potentially reduce drug costs if barriers in the U.S. are removed or diminished.

Understanding the Part D spending dynamics of heart failure patients26 July 2018 - By Gabriela Dieguez and Harsha Mirchandani and Jared Hirsch - Article

Understanding pharmacy spending by heart failure patients requires an evaluation of the complex interactions between members, payers, manufacturers, and the government in Part D.

Comprehensive Care for Joint Replacement Performance Year 1 results: Key considerations08 January 2018 - By Pamela M. Pelizzari and Harsha Mirchandani - Article

This paper combines data from the report of Performance Year 1 (PY1) results and other publically available sources to compare hospitals that received payments in the Comprehensive Care for Joint Replacement model PY1 to those that did not.

Impact of prescription drug copay regulatory action on ACA exchange plans in Colorado and Montana18 July 2017 - By Gabriela Dieguez and Harsha Mirchandani - Article

This report examines the Colorado and Montana markets before and after the guidance regarding fixed dollar prescription drug copays and no prescription drug deductible or coinsurance requirements in certain health plans.

Evolution of the use of restrictions in commercial formularies03 November 2016 - By Gabriela Dieguez and Harsha Mirchandani - Article

This report uses drug formulary data covering over 150 million lives in the U.S. to examine trends in the use of prior authorization, step therapy, and formulary exclusion in commercial formularies for the years 2011 to 2016.


  • Work at Milliman

    • “I was offered a chance to come in, shake things up, create something."
    Work at Milliman